دورية أكاديمية
Metabolism in stem cell-driven leukemia: parallels between hematopoiesis and immunity.
| العنوان: | Metabolism in stem cell-driven leukemia: parallels between hematopoiesis and immunity. |
|---|---|
| المؤلفون: | Rattigan KM; Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Zarou MM; Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom., Helgason GV; Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. |
| المصدر: | Blood [Blood] 2023 May 25; Vol. 141 (21), pp. 2553-2565. |
| نوع المنشور: | Review; Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2021- : [New York] : Elsevier Original Publication: New York, Grune & Stratton [etc.] |
| مواضيع طبية MeSH: | Hematopoiesis* , Leukemia*/metabolism, Humans ; Glycolysis ; Oxidation-Reduction ; Neoplastic Stem Cells/metabolism ; Stem Cell Niche |
| مستخلص: | Our understanding of cancer metabolism spans from its role in cellular energetics and supplying the building blocks necessary for proliferation, to maintaining cellular redox and regulating the cellular epigenome and transcriptome. Cancer metabolism, once thought to be solely driven by upregulated glycolysis, is now known to comprise multiple pathways with great plasticity in response to extrinsic challenges. Furthermore, cancer cells can modify their surrounding niche during disease initiation, maintenance, and metastasis, thereby contributing to therapy resistance. Leukemia is a paradigm model of stem cell-driven cancer. In this study, we review how leukemia remodels the niche and rewires its metabolism, with particular attention paid to therapy-resistant stem cells. Specifically, we aim to give a global, nonexhaustive overview of key metabolic pathways. By contrasting the metabolic rewiring required by myeloid-leukemic stem cells with that required for hematopoiesis and immune cell function, we highlight the metabolic features they share. This is a critical consideration when contemplating anticancer metabolic inhibitor options, especially in the context of anticancer immune therapies. Finally, we examine pathways that have not been studied in leukemia but are critical in solid cancers in the context of metastasis and interaction with new niches. These studies also offer detailed mechanisms that are yet to be investigated in leukemia. Given that cancer (and normal) cells can meet their energy requirements by not only upregulating metabolic pathways but also utilizing systemically available substrates, we aim to inform how interlinked these metabolic pathways are, both within leukemic cells and between cancer cells and their niche. (© 2023 by The American Society of Hematology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).) |
| References: | Cancer Cell. 2018 Oct 8;34(4):659-673.e6. (PMID: 30270124) Cell Rep. 2016 Feb 2;14(4):966-977. (PMID: 26804912) Cell Stem Cell. 2013 Mar 7;12(3):329-41. (PMID: 23333149) Cancer Cell. 2011 Nov 15;20(5):674-88. (PMID: 22094260) Nat Rev Immunol. 2006 Feb;6(2):93-106. (PMID: 16491134) Arthritis Res Ther. 2017 Apr 11;19(1):76. (PMID: 28399896) Cancer Cell. 2021 Jul 12;39(7):999-1014.e8. (PMID: 34171263) Cell. 2021 Aug 5;184(16):4186-4202.e20. (PMID: 34216540) Nat Rev Immunol. 2020 Jan;20(1):55-70. (PMID: 31406325) Sci Transl Med. 2019 Oct 30;11(516):. (PMID: 31666400) J Proteome Res. 2019 Jan 4;18(1):169-181. (PMID: 30362351) Cell. 2016 Oct 20;167(3):829-842.e13. (PMID: 27745970) Cell Metab. 2019 Jun 4;29(6):1410-1421.e4. (PMID: 30905671) Cell Metab. 2016 Jan 12;23(1):27-47. (PMID: 26771115) Blood. 2019 Dec 12;134(24):2183-2194. (PMID: 31697807) Blood. 2016 Jul 14;128(2):253-64. (PMID: 27257182) N Engl J Med. 2006 Dec 7;355(23):2408-17. (PMID: 17151364) Cell Metab. 2022 Jun 7;34(6):874-887.e6. (PMID: 35504291) Nat Metab. 2019 Feb;1(2):177-188. (PMID: 31245788) Cell Metab. 2021 Jan 5;33(1):145-159.e6. (PMID: 33357456) Cancer Discov. 2019 Jul;9(7):890-909. (PMID: 31048321) Blood. 2006 Jun 1;107(11):4532-9. (PMID: 16469872) Nature. 2017 Sep 28;549(7673):476-481. (PMID: 28825709) Trends Cell Biol. 2018 Dec;28(12):976-986. (PMID: 29935893) Cell Metab. 2020 Mar 3;31(3):518-533.e10. (PMID: 32004476) Cell Metab. 2020 Aug 4;32(2):154-175. (PMID: 32649859) Cell Stem Cell. 2016 Jul 7;19(1):23-37. (PMID: 27374788) Clin Transl Immunology. 2019 Dec 24;8(12):e1098. (PMID: 31890207) Cell Rep. 2020 Mar 3;30(9):2889-2899.e6. (PMID: 32130894) Nature. 2017 May 25;545(7655):500-504. (PMID: 28514443) Cell Rep. 2022 Apr 26;39(4):110752. (PMID: 35476984) Leukemia. 2021 Jun;35(6):1539-1551. (PMID: 33707653) Nat Med. 2018 Dec;24(12):1859-1866. (PMID: 30420752) Blood. 2007 Oct 15;110(8):3056-63. (PMID: 17595331) Exp Hematol. 2018 Feb;58:52-58. (PMID: 28947392) Nat Metab. 2019 Mar;1(3):390-403. (PMID: 31535081) Blood. 2005 Apr 1;105(7):2640-53. (PMID: 15618470) Nature. 2017 Nov 16;551(7680):384-388. (PMID: 29144447) Nature. 2019 Apr;568(7750):117-121. (PMID: 30814728) Cell Metab. 2019 Apr 2;29(4):1003-1011.e4. (PMID: 30773464) Cell. 2008 Dec 12;135(6):1118-29. (PMID: 19062086) J Nutr. 2009 Jun;139(6):1228S-1235S. (PMID: 19403716) Cell Stem Cell. 2010 Sep 3;7(3):391-402. (PMID: 20804974) Blood. 2013 Aug 1;122(5):749-58. (PMID: 23733335) Nature. 2018 Apr;556(7700):249-254. (PMID: 29615789) Mol Metab. 2022 Jan;55:101410. (PMID: 34863941) Cancer Discov. 2017 Jul;7(7):716-735. (PMID: 28416471) Nat Rev Drug Discov. 2022 Feb;21(2):141-162. (PMID: 34862480) Nat Cell Biol. 2017 Jun;19(6):614-625. (PMID: 28504706) Cell Stem Cell. 2014 Aug 7;15(2):169-84. (PMID: 24953180) Elife. 2021 Jun 16;10:. (PMID: 34132194) Nat Med. 2019 Mar;25(3):377-388. (PMID: 30842679) J Exp Med. 2008 Sep 29;205(10):2397-408. (PMID: 18809716) Nat Med. 2017 Jan;23(1):120-127. (PMID: 27869804) Cell Metab. 2021 Sep 7;33(9):1777-1792.e8. (PMID: 34375613) Blood. 2018 Apr 12;131(15):1639-1653. (PMID: 29463564) Development. 2014 Nov;141(22):4206-18. (PMID: 25371358) Cell Stem Cell. 2020 Nov 5;27(5):748-764.e4. (PMID: 32822582) Nat Med. 2018 Mar;24(3):360-367. (PMID: 29377004) Nat Cell Biol. 2017 Apr;19(4):271-281. (PMID: 28319093) Cell Metab. 2022 May 3;34(5):731-746.e9. (PMID: 35452600) Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. (PMID: 17956348) Dev Cell. 2005 Jun;8(6):907-14. (PMID: 15935779) Leukemia. 2020 Jun;34(6):1613-1625. (PMID: 31896780) Nature. 2015 Nov 19;527(7578):379-383. (PMID: 26560030) Dev Cell. 2020 Jul 20;54(2):239-255. (PMID: 32693057) Cell Metab. 2017 Feb 7;25(2):345-357. (PMID: 28111214) J Clin Invest. 2019 Jun 10;129(7):2685-2701. (PMID: 31180336) Nat Commun. 2021 Dec 8;12(1):7130. (PMID: 34880245) Blood. 2015 Apr 9;125(15):2386-96. (PMID: 25710880) Cell Stem Cell. 2014 Oct 2;15(4):507-522. (PMID: 25158935) Leukemia. 2021 Dec;35(12):3371-3382. (PMID: 34120146) Oncogene. 2018 May;37(21):2837-2849. (PMID: 29511345) Nat Metab. 2019 Jan;1(1):70-85. (PMID: 31198906) Nat Rev Mol Cell Biol. 2014 Apr;15(4):243-56. (PMID: 24651542) Cell Stem Cell. 2015 Jul 2;17(1):35-46. (PMID: 26095048) Nat Med. 2017 Oct;23(10):1234-1240. (PMID: 28920959) Cell Stem Cell. 2010 Sep 3;7(3):380-90. (PMID: 20804973) Cancer Med. 2016 Nov;5(11):3031-3040. (PMID: 27734609) Blood. 2015 Mar 26;125(13):2120-30. (PMID: 25631767) Mol Cell. 2022 Sep 1;82(17):3270-3283.e9. (PMID: 35973426) Cancer Cell. 2016 Nov 14;30(5):779-791. (PMID: 27746145) Cell Metab. 2020 Sep 1;32(3):391-403.e6. (PMID: 32763164) Cell Stem Cell. 2014 May 1;14(5):673-88. (PMID: 24792119) Cell Stem Cell. 2020 Mar 5;26(3):420-430.e6. (PMID: 32059807) Blood. 2015 Jun 25;125(26):4060-8. (PMID: 25896651) J Exp Med. 2005 Dec 5;202(11):1599-611. (PMID: 16330818) Cancer Cell. 2019 Oct 14;36(4):369-384.e13. (PMID: 31543463) Nat Cancer. 2020 Oct;1(10):998-1009. (PMID: 33479702) Ulster Med J. 2007 Jan;76(1):8-17. (PMID: 17288299) Cell Metab. 2022 Jan 4;34(1):90-105.e7. (PMID: 34986341) Sci Adv. 2020 Oct 9;6(41):. (PMID: 33036978) Nat Commun. 2016 Oct 12;7:13125. (PMID: 27731316) Mol Cell. 2021 Jan 21;81(2):386-397.e7. (PMID: 33340488) Mol Cell. 2020 Oct 15;80(2):263-278.e7. (PMID: 33022274) Blood. 2017 Oct 5;130(14):1649-1660. (PMID: 28733324) Leukemia. 2022 Feb;36(2):416-425. (PMID: 34462525) Nature. 2019 Aug;572(7768):254-259. (PMID: 31316209) Nature. 2017 Apr 19;544(7650):372-376. (PMID: 28425994) J Exp Med. 2017 Oct 2;214(10):2875-2887. (PMID: 28878000) Cancer Discov. 2019 Sep;9(9):1228-1247. (PMID: 31189531) Sci Immunol. 2022 Apr 29;7(70):eabm8161. (PMID: 35486677) Sci Adv. 2021 Mar 10;7(11):. (PMID: 33692103) Leukemia. 2019 Jun;33(6):1400-1410. (PMID: 30622285) Nat Cancer. 2020 Dec;1(12):1176-1187. (PMID: 33884374) Cell. 2021 Aug 5;184(16):4168-4185.e21. (PMID: 34216539) Cell. 2017 Sep 7;170(6):1079-1095.e20. (PMID: 28823558) Science. 2016 Dec 2;354(6316):1152-1155. (PMID: 27934766) Blood. 2014 May 22;123(21):3316-26. (PMID: 24705490) Blood. 2006 Mar 15;107(6):2311-6. (PMID: 16291588) Cell Stem Cell. 2021 Nov 4;28(11):1982-1999.e8. (PMID: 34450065) Nat Cancer. 2021 Nov;2(11):1204-1223. (PMID: 35122057) Int J Hematol. 2019 Jan;109(1):18-27. (PMID: 30219988) Hematology Am Soc Hematol Educ Program. 2004;:80-97. (PMID: 15561678) Cell Stem Cell. 2013 Jan 3;12(1):62-74. (PMID: 23290137) Nature. 2017 Nov 2;551(7678):115-118. (PMID: 29045397) Cell Metab. 2021 May 4;33(5):1027-1041.e8. (PMID: 33770508) Blood. 2012 Feb 9;119(6):1501-10. (PMID: 22184410) Cell Metab. 2022 Jun 7;34(6):818-835.e7. (PMID: 35508169) Cell Stem Cell. 2007 Dec 13;1(6):635-45. (PMID: 18371405) Nat Rev Cancer. 2012 Jul 24;12(8):513-26. (PMID: 22825216) Blood. 2019 Nov 21;134(21):1832-1846. (PMID: 31511238) J Immunol. 2015 Jul 15;195(2):450-463. (PMID: 26071560) Blood Cancer J. 2021 Feb 22;11(2):41. (PMID: 33619261) Cell Metab. 2018 Feb 6;27(2):428-438.e5. (PMID: 29337136) Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):2478-2483. (PMID: 29463741) Nature. 2017 Feb 23;542(7642):479-483. (PMID: 28192788) Science. 2020 Apr 3;368(6486):85-89. (PMID: 32241947) Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204) Blood. 2019 Jul 25;134(4):389-394. (PMID: 31101624) Cancer Cell. 2016 Nov 14;30(5):792-805. (PMID: 27908736) Cell Metab. 2019 Jun 4;29(6):1243-1257.e10. (PMID: 30827861) Nat Med. 2023 Jan;29(1):115-126. (PMID: 36658425) Nature. 2018 Jan 11;553(7687):212-216. (PMID: 29323290) Nat Immunol. 2018 Jan;19(1):85-97. (PMID: 29167569) Nat Rev Cancer. 2021 Dec;21(12):753-766. (PMID: 34417571) Nat Med. 2018 Jul;24(7):1036-1046. (PMID: 29892070) Blood Adv. 2021 Oct 26;5(20):4233-4255. (PMID: 34507353) N Engl J Med. 1969 Nov 6;281(19):1028-34. (PMID: 4898857) Nat Rev Cancer. 2020 Mar;20(3):158-173. (PMID: 31907378) Cell Stem Cell. 2018 May 3;22(5):627-638. (PMID: 29727678) Leukemia. 2015 Jun;29(6):1253-66. (PMID: 25482130) Blood. 2006 Feb 1;107(3):924-30. (PMID: 16219798) Cell Metab. 2020 Apr 7;31(4):852-861.e6. (PMID: 32268116) Blood. 2017 Mar 9;129(10):1320-1332. (PMID: 28049638) Wiley Interdiscip Rev Syst Biol Med. 2010 Nov-Dec;2(6):640-53. (PMID: 20890962) Cell Stem Cell. 2021 Mar 4;28(3):514-523.e9. (PMID: 33621486) EMBO Rep. 2015 Sep;16(9):1164-76. (PMID: 26209246) Leukemia. 2022 Jan;36(1):1-12. (PMID: 34561557) Int J Cancer. 2018 Apr 1;142(7):1490-1502. (PMID: 29168171) Nat Cell Biol. 2021 Jan;23(1):75-86. (PMID: 33420490) Oncotarget. 2015 Feb 28;6(6):3861-73. (PMID: 25738356) J Immunol Res. 2022 Feb 15;2022:3210200. (PMID: 35211629) |
| معلومات مُعتمدة: | 29754 United Kingdom CRUK_ Cancer Research UK; C57352/A29754 United Kingdom CRUK_ Cancer Research UK; A25142 United Kingdom CRUK_ Cancer Research UK |
| تواريخ الأحداث: | Date Created: 20230112 Date Completed: 20230529 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC10646800 |
| DOI: | 10.1182/blood.2022018258 |
| PMID: | 36634302 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1528-0020 |
|---|---|
| DOI: | 10.1182/blood.2022018258 |